Related references
Note: Only part of the references are listed.Baseline prevalence and longitudinal evolution of non-motor symptoms in early Parkinson's disease: the PPMI cohort
Tanya Simuni et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2018)
Longitudinal CSF biomarkers in patients with early Parkinson disease and healthy controls
Brit Mollenhauer et al.
NEUROLOGY (2017)
Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease
Chelsea Caspell-Garcia et al.
PLOS ONE (2017)
Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan)
Donald G. Grosset et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
A Randomized Clinical Trial of High-Dosage Coenzyme Q10 in Early Parkinson Disease No Evidence of Benefit
M. Flint Beal et al.
JAMA NEUROLOGY (2014)
Disease duration and the integrity of the nigrostriatal system in Parkinson's disease
Jeffrey H. Kordower et al.
BRAIN (2013)
Calibration of unified Parkinson's disease rating scale scores to Movement Disorder Society-unified Parkinson's disease rating scale scores
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2012)
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek et al.
PROGRESS IN NEUROBIOLOGY (2011)
Systematic Review of Levodopa Dose Equivalency Reporting in Parkinson's Disease
Claire L. Tomlinson et al.
MOVEMENT DISORDERS (2010)
Determinants of the Timing of Symptomatic Treatment in Early Parkinson Disease The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience
Sotirios A. Parashos et al.
ARCHIVES OF NEUROLOGY (2009)
A Double-Blind, Delayed-Start Trial of Rasagiline in Parkinson's Disease
C. Warren Olanow et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Movement Disorder Society-Sponsored Revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale Presentation and Clinimetric Testing Results
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2008)
Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease
Ira Shoulson et al.
NEUROLOGY (2007)
Movement disorder society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): Process, format, and clinimetric testing plan
Christopher G. Goetz et al.
MOVEMENT DISORDERS (2007)
A responsive outcome for Parkinson's disease neuroprotection futility studies
JJ Elm et al.
ANNALS OF NEUROLOGY (2005)
Non-linearity of Parkinson's disease progression: implications for sample size calculations in clinical trials
P Guimaraes et al.
CLINICAL TRIALS (2005)
Practice parameter: Initiation of treatment for Parkinson's disease: An evidence-based review - Report of the quality standards subcommittee of the American Academy of Neurology
JM Miyasaki et al.
NEUROLOGY (2002)
Share Paper
